Synonym Raises $20 Million Series A Funding Round

We're very pleased to announce that Synonym has just wrapped up a $20M Series A funding round. Our latest funding is co-led by GS Futures, the venture arm of GS Group, one of South Korea's largest conglomerates with significant holdings that intersect with biomanufacturing. When we messaged their Managing Partner Taehong Huh to ask him to sum up why he's investing, he said: "Because Synonym is solving one of the biggest bottlenecks in sustainable manufacturing -- you're translating biological innovation into reliable, scalable production. You guys are laying an overlooked yet crucial foundation for accelerating corporate and government adoption of biomaterials."

We're grateful for GS's vote of confidence and for our other investors, including Squad Capital, Zero Infinity Partners, Giant Ventures, Andreessen Horowitz, Cerberus Capital Management, Black Optal Ventures, IQT, Clocktower Ventures, Phenomen Ventures, RTP Global, and Siddhi Capital among others.

I also want to highlight the amazing team behind Synonym's success, including my co-founder Joshua Lachter, who has been a relentless supporter of the bioeconomy, Brentan Alexander and Crystal Bleecher, whose leadership ignites the passion within our two engineering teams, Mark Fridlyand, who keeps our ops and finances in check, and everyone else at Synonym. You are the best and I'm very proud of you joining Joshua and me on this journey.

We're using the funds to double-down on working with some of the leading companies in the world on rejuvenating their supply chains. So if you think about R&D and innovation at a large organization in health and beauty, personal care, apparel, food, agriculture, specialty chemicals, and beyond, please reach out.

Follow Synonym and think of ways to make the world's supply chains more efficient. Let's work on that together!